Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website


Immunogen reported $201.25M in Cash and Equivalent for its fiscal quarter ending in March of 2023.

Cash And Equivalent Change
Agios Pharmaceuticals AGIO:US USD 104.14M 35.12M
Amgen AMGN:US USD 31.56B 22.26B
Astellas Pharma 4503:JP JPY 376.84B 4.98B
AstraZeneca AZN:LN USD 6.23B 66M
Bluebird Bio BLUE:US USD 239.04M 126.04M
Bristol-Myers Squibb BMY:US USD 9B 128M
Eli Lilly LLY:US USD 3.55B 1.48B
Emergent BioSolutions EBS:US USD 430.2M 212.4M
Exelixis EXEL:US USD 540.6M 39.4M
Halozyme Therapeutics HALO:US USD 96.38M 137.81M
Heron Therapeutics HRTX:US USD 27.09M 11.73M
Immunogen IMGN:US USD 201.25M 73.89M
Intrexon XON:US USD 9.74M 4.88M
Karyopharm Therapeutics KPTI:US USD 84.06M 193.9M
MacroGenics MGNX:US USD 224.26M 115.38M
Nektar Therapeutics NKTR:US USD 76.96M 11.27M
Novartis NVS:US USD 12B 4.48B
Regeneron Pharmaceuticals REGN:US USD 3.92B 810.4M
Roche Holding ROG:VX 4.99B 676M
Seattle Genetics SGEN:US USD 335.85M 15.91M